---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000003"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:15:50.666067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127

## Summary
- Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.
- NX-2127 Phase 1 partial clinical hold; Nurix expects to resolve with new drug product in ongoing trial.
- Gilead licensed oral IRAK4 degrader NX-0479 for $20M fee; up to $425M milestones plus tiered royalties.
- Pfizer (Seagen) collaboration for Degrader-Antibody Conjugates; $60M upfront, up to $3.4B milestones.
- Cash of $329M (Aug 2023) plus $60M from Pfizer; runway into H2 2025.

## SEC filing metadata
- accession: 0001549595-24-000003
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000003/0001549595-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000003/nrix-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000003
- JSON: https://secwatch.observer/filing/0001549595-24-000003.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.